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Aims Dysfunctional matrix turnover is present at sites of abdominal aortic aneurysm (AAA) and leads to the accumulation
of monomeric tropoelastin rather than cross-linked elastin. We used a gadolinium-based tropoelastin-specific mag-
netic resonance contrast agent (Gd-TESMA) to test whether quantifying regional tropoelastin turnover correlates
with aortic expansion in a murine model. The binding of Gd-TESMA to excised human AAA was also assessed.
....................................................................................................................................................................................................
Methods
and results
We utilized the angiotensin II (Ang II)-infused apolipoprotein E gene knockout (ApoE-/-) murine model of aortic di-
lation and performed in vivo imaging of tropoelastin by administering Gd-TESMA followed by late gadolinium en-
hancement (LGE) magnetic resonance imaging (MRI) and T1 mapping at 3 T, with subsequent ex vivo validation. In a
cross-sectional study (n= 66; control = 11, infused = 55) we found that Gd-TESMA enhanced MRI was elevated and
confined to dilated aortic segments (control: LGE=0.13 ± 0.04 mm
2, control R1= 1.1 ± 0.05 s
-1 vs. dilated LGE
=1.0 ± 0.4 mm2, dilated R1 =2.4 ± 0.9 s
-1) and was greater in segments with medium (8.0 ± 3.8 mm3) and large
(10.4 ± 4.1 mm3) compared to small (3.6 ± 2.1 mm3) vessel volume. Furthermore, a proof-of-principle longitudinal
study (n= 19) using Gd-TESMA enhanced MRI demonstrated a greater proportion of tropoelastin: elastin expres-
sion in dilating compared to non-dilating aortas, which correlated with the rate of aortic expansion. Treatment with
pravastatin and aspirin (n= 10) did not reduce tropoelastin turnover (0.87 ± 0.3 mm2 vs. 1.0 ± 0.44 mm2) or aortic
dilation (4.86 ± 2.44 mm3 vs. 4.0 ± 3.6 mm3). Importantly, Gd-TESMA-enhanced MRI identified accumulation of tro-
poelastin in excised human aneurysmal tissue (n= 4), which was confirmed histologically.
....................................................................................................................................................................................................
Conclusion Tropoelastin MRI identifies dysfunctional matrix remodelling that is specifically expressed in regions of aortic aneu-
rysm or dissection and correlates with the development and rate of aortic expansion. Thus, it may provide an addi-
tive imaging marker to the serial assessment of luminal diameter for surveillance of patients at risk of or with estab-
lished aortopathy.
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Graphical Abstract
1. Introduction
Abdominal aortic aneurysm (AAA) disease currently affects about 2%
of men over 65 years of age.1 Aneurysmal segments can expand over
time and have an elevated risk of rupture, which is associated with
high mortality (90%).2 Anatomical imaging for measurement of aor-
tic diameter is currently used for the diagnosis and surveillance of
AAA, where the risk of rupture correlates with aneurysmal size.3
However, as the majority of patients with AAA are asymptomatic,
confirmed diagnoses often arise due to incidental findings or from
dedicated ultrasound-based screening programmes in at-risk popula-
tions.4,5 Intervention using surgical or endovascular techniques is rec-
ommended when AAA diameters exceed 55 mm, expand rapidly
(>10 mm/year) or in the context of symptomatic disease. However,
predicting the progression and outcome of AAA remains complex
due to the non-linearity of expansion rates6 and the absence of rup-
ture or adverse events in a significant proportion (40%) of large
aneurysms (>70–100 mm).7 Conversely, <_20% of ruptured AAA is
<55 mm in diameter. Thus, there is a currently, unmet clinical need
to improve identification of high-risk patients and better inform subse-
quent management decisions. Molecular imaging strategies that char-
acterize AAA composition and biology could improve existing risk
stratification approaches that are solely derived from clinical and ana-
tomical information.
Several pathogenic mechanisms have been implicated in aortic aneu-
rysm formation and expansion including local inflammation,8
2 B. Lavin et al.
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extracellular matrix (ECM) remodelling,9–12 increased elastolysis,8 and
oxidative stress.13 Elastin is an abundant ECM protein of the aortic wall,
the remodelling of which is crucial for the progression of AAAs.9,10,12
Elastin is formed by cross-linking of the 72 kDa soluble precursor tro-
poelastin molecule,14 by lysyl oxidase (LOX). Although it is well-known
that active elastolysis leads to thinning and weakening of the elastic la-
mellae of the media during AAA formation,9,10 de novo synthesis of elas-
tin fibres that also occurs has received little attention. Studies have
shown that disordered elastogenesis is active in matrix remodelling in
AAA15 and Marfan’s syndrome.16,17 However, newly synthesized tro-
poelastin monomers secreted from vascular smooth muscle cells 18–20
and macrophages21 frequently fail to cross-link into polymeric elastin
fibres12,21–23 as a result of the reduced expression, absence or inactiva-
tion of LOX24–29 or any of the components of the microfibrillar scaffold
required for fibre assembly.30–32
Because of their central role in the pathogenesis of AAA, in vivo
imaging of aortic wall inflammation or matrix remodelling have
been achieved using ultrasmall superparamagnetic particles of iron
oxide (USPIOs),33 collagen-binding,34 and elastin-specific MRI con-
trast agents (Gd-ESMA).35,36 The clinical utility of USPIO-enhanced
MRI was assessed in a Phase II study, in which imaging of vascular in-
flammation was shown to be predictive of aneurysmal growth and
adverse events but did not provide incremental value beyond as-
sessment of clinical risk factors.33 As dysfunctional matrix remodel-
ling contributes to the reduction of vessel wall integrity and may
promote aneurysm/dissection formation and rupture, we assessed
the utility of a tropoelastin-specific magnetic resonance (MR) con-
trast agent in a murine model and excised tissue from human AAA.
The results demonstrate that tropoelastin MRI leads to specific en-
hancement of aortic segments that develop aneurysm or dissection,
which may improve risk assessment compared to the serial assess-
ment of aortic diameter alone.
2. Methods
We utilized the Angiotensin II (Ang II)-infused ApoE-/- murine model of
aortic aneurysm and dissection, which shares some characteristics of the
human disease including luminal dilation, macrophage infiltration, medial
degradation, and thrombus.11,12,37–39 The term aortic dilation/expansion
used in this article refers to both conventional aortic aneurysms and
expanding aortic dissections as previously described to occur in this ani-
mal model.12,39,41 In a cross-sectional study, ApoE-/- mice (n= 66) were
imaged at a clinical 3 T MRI scanner before and at 1, 2, 3, and 4 weeks af-
ter infusion of Ang II (n= 8/per group). Magnetic resonance angiography
(MRA), late gadolinium enhancement (LGE), and T1-mapping images
were acquired. Ang II-infused mice treated with pravastatin and aspirin
(n= 10) were scanned at 4 weeks. In a longitudinal study (n= 19), Ang II-
infused mice were scanned weekly for up to 4 weeks. Excised murine
aortas were collected for histology (n= 4), western blotting (n= 3), and
inductively coupled plasma mass spectrometry (n= 4) per time point.
Excised human aortic aneurysm tissues (n= 4) were scanned and ana-
lysed ex vivo. The tropoelastin and elastin-binding agents were adminis-
tered intravenously on consecutive days (0.2 mmol/kg). Numeric data
were analysed for normality and the significance was determined using
the appropriate non-parametric test. Box–whisker plots were used in
the figures, whereas the numeric data presented in the abstract are
mean ± standard deviation. Animal procedures and use of human
samples were approved by the appropriate committees. Detailed
methods and statistics are described in the Supplementary material on-
line, Figure S1.
3. Results
In vivo MRA showing examples of aortic dilation with ex vivo validation
and a summary of Ang II-induced aortic aneurysms and dissections ob-
served in our study are demonstrated in the Supplementary material on-
line, Figure S2.
3.1 Gd-TESMA MRI demonstrates elevated
tropoelastin expression confined to dilated
aortic segments
As elastin is abundant throughout normal and dilated aortic segments,
we performed imaging using the elastin (Gd-ESMA) and tropoelastin
(Gd-TESMA) specific MR agents in control and Ang II-infused ApoE-/-
mice (24 h apart) to compare total elastin and tropoelastin expression
within the aortic wall, given that Gd-ESMA binds equally to both cross-
linked elastin and tropoelastin.35 As previously demonstrated,40 Gd-
ESMA resulted in circumferential enhancement of the control aortic wall
consistent with binding to cross-linked elastin, which is an integral struc-
tural component of the normal aorta (Figure 1A–D). Conversely, there
was little enhancement of control vessel wall after injection of Gd-
TESMA, demonstrating that tropoelastin expression is not present or
up-regulated in the absence of disease (Figure 1E and F), which was veri-
fied histologically and as previously shown.40 In an Ang II-infused ApoE–/–
mouse (Figure 1G), LGE-MRI through a non-dilated segment of the aorta
showed circumferential enhancement with Gd-ESMA (Figure 1H–J) and
little enhancement with Gd-TESMA (Figure 1K and L). Conversely, LGE-
MRI through a dilated segment of the aorta showed uptake of both
agents (Figure 1M–Q). Comparatively, Gd-ESMA enhancement resulted
in a strong circumferential enhancement of the dilation (Figure 1M–O),
whereas Gd-TESMA of enhancement was patchy (Figure 1P and Q).
Quantitatively, whilst the Gd-ESMA enhanced area was larger compared
to that of Gd-TESMA in control mice and animals infused with Ang II but
did not develop aortic dilations, similar areas of enhancement were mea-
sured in dilated aortic segments for both contrast agents (Figure 1R).
Fused three-dimensional reformatted MRA and Gd-TESMA enhanced
images together with a graph show the changes in aortic and vessel wall
enhanced areas from consecutive slices along the aorta in another Ang
II-infused mouse (Figure 1S and T). A comparison of the quantitative dif-
ferences between Gd-ESMA and Gd-TESMA are illustrated in
Supplementary material online, Figure S3. These data demonstrate that
unlike Gd-ESMA, the uptake of Gd-TESMA is specific for dilated seg-
ments of the aorta, consistent with dysfunctional matrix turnover in
these regions.
3.2 MRI of tropoelastin shows
enhancement at sites of aortic aneurysm
or dissection
A three-dimensional reformatted angiogram acquired from an Ang II-
infused ApoE–/– mouse for 2 weeks showed a non-dilated segment of
the aorta and two separate regions of aortic dilation (Figure 2A). MRI sli-
ces acquired through the non-dilated segment of the aorta showed a
normal aortic diameter (Figure 2B) and weak Gd-TESMA enhancement
(Figure 2C and D). This was verified histologically by the absence of aortic
dilation (Figure 2E) and lack of tropoelastin monomers (Figure 2F and G).
MRI of tropoelastin correlates with aortic expansion 3
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In a distal segment (suprarenal), angiography showed a region of aortic
aneurysm (Figure 2H) and vessel wall Gd-TESMA enhancement (Figure 2I
and J) that was validated histologically by the deposition of tropoelastin
within the remodelled media (Figure 2K–M). At the second level of aortic
dilation, angiography and quantitative flow images showed formation of a
false lumen (Figure 2N) with retrograde blood flow (Figure 2T–V) indica-
tive of an expanding aortic dissection with a medial tear, as previously de-
scribed for this model.39,41 In this case, Gd-TESMA enhancement was
observed in the vessel wall between the true and false lumens, with cir-
cumferential enhancement of the false lumen margins (Figure 2O–P). The
presence of dual (true and false) lumens was confirmed by histology
(Figure 2Q), with abundant tropoelastin (Figure 2R and S) corresponding
to areas of Gd-TESMA enhancement seen on in vivo MRI.
3.3 Quantitative MRI and tissue analysis
shows that tropoelastin accumulation is
confined within dilated aortic segments
Quantitative MRI measurements showed larger Gd-TESMA enhanced
area and higher vessel wall R1 in dilated, compared to non-dilated and
control aortas (Figure 3A and B). Ex vivo ICP-MS, immunohistochemistry,
and western blotting showed increased gadolinium concentration and
tropoelastin accumulation in dilated compared to non-dilated and con-
trol aortas (Figure 3C–F). Tropoelastin deposition was higher in medium
and large-size compared to small-size dilated aortic segments as mea-
sured by both in vivo Gd-TESMA enhanced MRI and immunohistochem-
istry (Figure 3G–H). Correlation analyses showed good agreement
between MRI and histological measurements (Supplementary material
online, Figure S4). Quantification of soluble tropoelastin in serum showed
no differences between controls, untreated, and treated Ang II-infused
mice with dilated aortas (Supplementary material online, Figure S5).
3.4 Longitudinal MRI of tropoelastin shows
that tropoelastin accumulation correlates
with aortic expansion
Next, we performed a proof-of-concept longitudinal study, in which 19
Ang II-infused ApoE-/- mice were scanned weekly for up to 4 weeks to in-
vestigate the effect of tropoelastin accumulation on the rate of aortic ex-
pansion and incidence of rupture. One mouse died because of a
Figure 1 Gd-TESMA MRI demonstrates elevated tropoelastin expression confined to dilated aortic segments. (A–Q) MRA and LGE-MRI of a control (A–F)
and an Ang II-infused ApoE-/- mouse with aortic dilation (G–Q) scanned with the elastin (B–D, H–J, and M–O) and 24 h later the tropoelastin contrast
agents (E and F; K and L; and P and Q). (R). Box–whisker plots of the LGE-MRI area shows that, unlike Gd-ESMA, the uptake of Gd-TESMA is specific for
dilated segments (n= 14) of the aorta, consistent with dysfunctional matrix turnover in these regions, and is low in control (n= 5) and Ang II-infused
mice without dilation (n= 6). Quantitative data were analysed by a Wilcoxon signed rank test for paired samples. (S and T) Fusion of reformatted MRA
and LGE-MRI images from an Ang II-infused ApoE-/- mouse, after administration of Gd-TESMA, and graph show that the uptake of the tropoelastin
contrast agent is confined within the dilated wall. Ao, aorta; LRA: left renal artery; MIP, maximum intensity projection; RRA, right renal artery.
4 B. Lavin et al.
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..ruptured aorta 8 days after infusion and three mice died from undeter-
mined reasons. Of the 15 remaining mice, 10 had dilating and five had
non-dilating aortas. An example of an animal with increased Gd-TESMA
enhancement in a non-dilated aorta, which subsequently enlarged is
shown in Figure 4A and B. This animal had an angiographically normal size
aorta and Gd-TESMA enhancement 1 week after Ang II-infusion (Figure
4A). Subsequently, at Week 4 there was a 33.86% dilation of the aorta
and further increase in Gd-TESMA enhancement (Figure 4B). An example
of an animal with increased Gd-TESMA enhancement in a dilated aorta
which further enlarged by Week 4 is shown in Figure 4C and D. This ani-
mal had an angiographically dilated aorta and higher Gd-TESMA en-
hancement 1 week after Ang II-infusion (Figure 4C). At Week 4, there
was a 152.6% expansion of the aorta and formation of a false lumen.
Importantly, Gd-TESMA enhanced images showed a significant increase
in tropoelastin accumulation around the aortic dilation. The segmented
tropoelastin was super-imposed on the segmented aortic lumen as seen
by Gd-TESMA MRI and MRA, respectively. Quantitatively, dilating aortas
had higher Gd-TESMA enhancement compared with non-dilating aortas
at all-time points (Figure 4E). The rate of aortic expansion, as measured
using MRA, correlated with the rate of tropoelastin accumulation, as
measured by Gd-TESMA enhancement (Figure 4F). The Gd-TESMA en-
hancement measured at 2 weeks after Ang II-infusion correlated with
the final aortic expansion (Figure 4G). When the volume of Gd-TESMA
enhancement was normalized to vessel wall size, we found a higher pro-
portion of Gd-TESMA in dilating compared to non-dilating aortas
3 weeks after Ang II-infusion (Figure 4H). The proportion of Gd-TESMA
correlated with aortic size (Figure 4I) and the rate of aortic expansion
(Figure 4J).
3.5 Pravastatin and aspirin treatment did
not reduce tropoelastin accumulation or
aortic dilation
We then tested whether quantifying tropoelastin turnover could be
used as an imaging marker to assess treatment response. As aspirin and
statins reduce clinical events and are commonly prescribed together in
patients with established coronary artery disease, we assessed whether
administration of these therapies reduces tropoelastin expression in this
model.42,43 Therefore, we treated a subgroup of Ang II-infused mice with
pravastatin and aspirin for 30 days. In our study, seven out of the 10
(70%) treated mice developed aortic dilation, which was similar to the
rate observed for untreated animals. MRI images of a treated mouse are
shown in Figure 5. The three-dimensional reformatted angiogram shows
the aortic dilation (Figure 5A) and the transverse images reveal a medial
Figure 2 MRI of tropoelastin shows enhancement at sites of aortic aneurysm or dissection. (A) A reformatted MRA of an Ang II-infused ApoE-/- mouse
shows two regions of aortic dilation. (B–G) MRA, LGE-MRI, and histology of a non-dilated segment show a normal aortic size, low enhancement after admin-
istration of Gd-TESMA, and lack of tropoelastin, respectively. (H–M) At the level of the first aortic dilation, there is vascular enhancement of the aneurysm
after administration of Gd-TESMA that co-localized with the accumulation of tropoelastin as verified histologically. (N–P and T–V) At the level of the second
aortic dilation, MRI images show the formation of a false lumen indicative of an aortic dissection, with aortic enhancement after administration of Gd-
TESMA and retrograde blood flow. (Q–S) Histology verified the formation of two lumens and the accumulation of tropoelastin in areas where vascular en-
hancement was observed in vivo using the tropoelastin agent. Ao, aorta; FL, false lumen.
MRI of tropoelastin correlates with aortic expansion 5
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..dissection and a false lumen (Figure 5B–D). Gd-TESMA enhancement oc-
curred in the vessel wall between the true and false lumens (Figure 5E
and F). In vivo MRI showed no differences in the aortic cross-sectional
and Gd-TESMA enhanced areas between treated and untreated animals
(Figure 5G and H).
3.6 Gd-TESMA MRI identifies tropoelastin
accumulation in human aortic aneurysms
To test the translational potential of our work, we imaged tissue
obtained from patients with AAA with the tropoelastin (Gd-TESMA)
and elastin (Gd-ESMA) contrast agents. Excised AAA (Figure 6A) was
imaged with a T2W scan (Figure 6B) to identify the vessel wall.
Subsequent, T1 mapping experiments before (Figure 6C) and after soak-
ing the tissue showed retention of both agents in the aneurysmal vessel
wall (Figure 6D–F) and ex vivo immunohistochemistry verified the accu-
mulation of tropoelastin in the media (Figure 6G–I).
4. Discussion
We investigated the role of tropoelastin as a new imaging marker of dys-
functional matrix turnover in aortic aneurysms and dissections in the
Ang II-infused ApoE-/- murine model and excised human aortic
Figure 3 Quantitative MRI and ex vivo tissue results show that tropoelastin accumulates within dilated aortas. (A and B) Quantitative Gd-TESMA LGE-MRI
measurements showed larger enhancement area and higher vessel wall R1 in dilated (n= 36), compared to non-dilated (n= 6) and control vessels (n= 6).
(C–F) ICP-MS (n= 4/group), immunohistochemistry (n= 4 for control, n= 17 for dilated), and western blotting (n= 3/group) verified the in vivo MRI findings
and showed increased gadolinium concentration and tropoelastin accumulation in dilated compare to non-dilated and control aortas. (G and H)
Tropoelastin accumulation was higher in medium and large-size compared to small-size dilation as measured by both in vivoMRI (n= 12/group) and immuno-
histochemistry (n= 6/group). Two groups were compared with a Mann–Whitney test and multiple groups with a Kruskal–Wallis ANOVA test followed by
a Dunn’s post hoc test.
6 B. Lavin et al.
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aneurysmal tissue. In vivo imaging of tropoelastin was performed using a
gadolinium-based tropoelastin-specific magnetic resonance contrast
agent (Gd-TESMA). Gd-TESMA enhanced MRI showed that tropoelastin
accumulation is elevated and confined to dilated aortic segments and
identifies aortic dilation with different morphological characteristics. Gd-
TESMA enhanced MRI also showed that the proportion of tropoelastin
in the vessel wall is higher in dilating compared to non-dilating aortas and
correlates with the rate of aortic expansion. Pravastatin and aspirin treat-
ment did not reduce the tropoelastin turnover or aortic dilation in this
animal model, possibly reflecting the lack of consistent evidence regard-
ing their efficacy for management of AAA in clinical studies. Importantly,
Gd-TESMA enhancement demonstrated accumulation of tropoelastin in
excised human aneurysms, highlighting the translational potential of this
imaging strategy. Our results suggest that tropoelastin MRI is a novel ap-
proach for the identification of dysfunctional matrix remodelling in aortic
disease, which correlates with the development and rate of aortic
dilatation.
Our cross-sectional study and quantitative analysis in mice showed
that the uptake of Gd-TESMA was confined to and higher in dilated com-
pared with non-dilated and control aortic segments and it was also
higher in aortic tissue from medium and large compared to small-dilated
aortic segments, suggesting that tropoelastin is a disease-specific marker
that correlates with the degree of aortic expansion. Importantly, in vivo
monitoring of vascular tropoelastin remodelling was detectable and fea-
sible at clinical field strengths. In vivo enhancement of the dilated aortic
segments and higher vascular R1 values were corroborated by the accu-
mulation of tropoelastin, as detected by ex vivo immunohistochemistry
and western blotting, and by higher gadolinium concentration as mea-
sured by inductively coupled plasma mass spectrometry. Consistent
with our results, the detrimental effects of increased elastolysis, oxidative
stress, and impaired elastin cross-linking in promoting aortic dilation
have also been previously reported in the Ang II-infused, the elastase-
perfused, the fibrillin-1 knock-out/Marfan syndrome, and the LOX
knock-out murine models.11–13,29,37,44–47
Figure 4 Longitudinal MRI of tropoelastin shows that tropoelastin accumulation correlates with aortic expansion. (A and B) MRA and Gd-TESMA en-
hanced images, show enhancement in a non-dilated aorta at Week 1 following Ang II-infusion, which subsequently dilates at Week 4. (C and D) MRA and
Gd-TESMA enhanced images, show a higher enhancement in an already dilated aorta at Week 1 following Ang II-infusion, which further dilates and accumu-
lates more tropoelastin at Week 4. (E) Dilating aortas contained more tropoelastin compared to non-dilating aortas at all times. (F) The rate of aortic expan-
sion correlates with the rate of tropoelastin deposition. (G) The Gd-TESMA enhanced area measured at 2 weeks after Ang II-infusion correlated with aortic
expansion measured at 4 weeks (E and G, n= 15). (H) Dilating aortas contain higher proportion of tropoelastin at Week 3 following Ang II infusion. (I) The
proportion of tropoelastin in the vessel wall correlates with aortic volume. (J) The increase in the proportion of tropoelastin correlates with the rate of aor-
tic expansion (H–J, n= 8). Two groups were compared with a Mann–Whitney test and multiple groups were compared with a Kruskal–Wallis followed by a
Dunn’s post hoc test. Ao, aorta; MIP, maximum intensity projection; FL, false lumen.
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Our results using excised human aortic aneurysms demonstrate that
the tropoelastin contrast agent maintains its specificity towards human
tropoelastin and can be detected using a clinical scanner, highlighting the
translational potential of our work. As dissected human thoracic aneur-
ysms are characterized by elevated elastin content with reduced insolu-
ble elastin indicative of ineffective maturation and cross-linking, there is
evidence for an imbalance between elastin synthesis and degradation in
effected aortic segments that could potentially be identified using a Gd-
TESMA MRI approach.21–23,48 This could be extended to patients with
genetic disorders of the ECM, such as cutis laxa and Marfan syndrome,
where altered elastin homoeostasis has also been identified.17,49 As mac-
rophages have been shown to be a source of tropoelastin, there is a pos-
sible link between aortic inflammation and disordered elastin synthesis in
the pathogenesis of AAA,21 which may also be present in atherosclerosis
Figure 5 Concurrent treatment with pravastatin and aspirin did not reduce tropoelastin accumulation or aortic dilation. (A) A reformatted angiogram ac-
quired from an Ang II-infused ApoE-/- mouse treated with pravastatin and aspirin shows a suprarenal dilation. (B–F) Cross-sectional MRA and Gd-TESMA en-
hanced images, showed enhancement of the aortic dissection. (G and H) Quantification of the aortic cross-sectional and Gd-TESMA enhanced areas were
similar between treated (n= 10) and untreated mice (n= 36). Quantitative data were compared with a non-parametric Mann–Whitney test. Ao, aorta; FL,
false lumen; MA, mesenteric artery; MIP, maximum intensity projection; RRA, right renal artery.
Figure 6 Gd-TESMA MRI identifies tropoelastin accumulation in human aortic aneurysms. (A) Ex vivo photograph of an aortic aneurysm in longitudinal
and transverse planes after suturing the ends for the imaging experiment. (B and C) A T2W image shows the remodelled vessel wall and a corresponding T1
map shows the baseline relaxation times. (D) A T1 map acquired after soaking the specimen in Gd-TESMA followed by washing in buffered saline to eliminate
unspecific binding shows uptake of the agent and reduction of the T1 relaxation time. (E) A repeated T1 mapping experiment after washing the specimen,
soaking it in Gd-ESMA, followed by another wash also showed a reduction of the T1 values. (F) Quantification of the relaxation rate (R1) changes shows sig-
nificant uptake of both agents in the aneurysmal wall. Quantitative data were analysed by a Wilcoxon signed rank test for paired samples (n= 4). (G–I)
Corresponding histology shows the tissue morphology and deposition of tropoelastin within the vessel wall.
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effecting small and medium-sized arteries. The current study expands on
previous work that assessed total elastin content, using Gd-ESMA, in
models of AAA35,36 through the development and application of a probe
(Gd-TESMA) that specifically targets tropoelastin in order to identify
areas of pathological elastin turnover that are only present in diseased
vessels.40 Here, we found that uptake of Gd-TESMA is confined within
dilated walls and, unlike Gd-ESMA, it eliminates signal from endoge-
nously present cross-linked elastin that exists in both control and dis-
eased vessels.
Our proof-of-principle longitudinal study in mice showed that the
proportion of tropoelastin is higher in dilating aortas and correlated with
the rate of aortic expansion. This finding has potential implications for
the screening or surveillance of aortic aneurysms and dissections with
non-invasive imaging. Currently, population screening of high-risk
patients including males, greater than 65 years of age with a history of
smoking has been established in some countries and is associated with
halving the mortality rate associated with AAA.4,5 However, continued
surveillance of AAA and prediction of expansion is challenging because
of the unpredictability and non-linearity of expansion rates6 despite the
development of reliable angiography techniques50 and standardized
reporting systems that offer excellent inter-observer agreement in
assessing vascular abnormalities. Addition of an imaging marker, such as
the tropoelastin, that can be quantified non-invasively and which corre-
lates with aortic expansion might have additive value in patient risk strati-
fication. This may be particularly important for patients in whom
treatment decisions are not straightforward, including patients with
aneurysms that are borderline for intervention (50–55 mm).
Furthermore, we observed elevated tropoelastin levels in both areas of
aneurysmal dilation and aortic dissection, likely indicating common path-
ophysiological links between these conditions that could potentially be
identified using a common imaging strategy with Gd-TESMA MRI. As
patients with underlying connective tissue disease have an increased inci-
dence of both aortic aneurysm formation and aortic dissection, molecu-
lar imaging of tropoelastin may be informative for both conditions that
appear to be driven by dysfunctional matrix remodelling.
Currently, there is no proven specific therapy that reduces aneurysm
growth.51 For this reason, we chose to administer a medication regimen
comprising of commonly prescribed therapies for patients with athero-
sclerotic vascular disease (i.e. aspirin and statins) to assess whether any
modulation of dysfunctional matrix turnover within the aortic aneurysm
and dissections could be observed using Gd-TESMA enhanced MRI. We
found that concurrent treatment with pravastatin and aspirin did not re-
duce tropoelastin accumulation, aneurysm formation or aortic dissection
in Ang II-infused ApoE-/- mice. Despite the unequivocal benefits of statins
in reducing the rate of plaque progression animal models52 and cardio-
vascular events in patients with coronary artery disease,53 there are con-
flicting data regarding the effect of statins in reducing aneurysm growth
and incidence of rupture, indicative of important aetiological differences
underlying these two vascular diseases.54 Similarly, statin-treatment in
Ang II-infused mice has yielded conflicting results.55,56 Preservation of
medial elastin lamellae via inhibition of matrix metalloproteinases and re-
duction of aortic diameter was reported only when pre-activated simva-
statin was administered subcutaneously,55 instead of orally for the same
duration, in Ang II-infused mice as reported here and in previous stud-
ies.56 As standard therapies for atherosclerosis have yielded mixed
results in the context of aortic disease, there is a need to identify novel
therapeutic targets such as the inhibition of c-Jun N-terminal kinase45
and miR-29b (microRNA)57 that showed aneurysm reduction via modu-
lation of ECM metabolism. In light of these results, molecular imaging of
tropoelastin could provide a surrogate marker for testing the efficacy of
novel therapies in translational studies.
The current study has some limitations. Firstly, although tropoelastin
expression was associated with aortic aneurysms and dissections, aortic
rupture with intra-abdominal haemorrhage did not occur in a sufficient
number of animals and thus, we were unable to test the value of imaging
tropoelastin in predicting vessel wall instability. Secondly, region-of-
interest analysis was performed manually because of the lack of an
automated/semi-automated software that could potentially decrease
user bias. However, there was a good inter-observer agreement for the
analysis of MRI data.
We show, for the first time, that molecular MRI using a tropoelastin
contrast agent at clinical field strengths can non-invasively quantify dys-
functional matrix remodelling, which was specifically observed at sites of
aortic aneurysm and dissection. Importantly, longitudinal assessment
demonstrated that the proportion of aortic tropoelastin expression cor-
related with the rate of aortic expansion that could have potential impli-
cations for screening and risk stratification of patients. Although, the
importance of disordered elastin turnover in aortic aneurysm/dissection
is well established,21–23,48 in vivo detection of dysfunctional elastin remod-
elling has been hampered by the lack of a clinically validated, non-invasive
diagnostic tool. An imaging strategy using the tropoelastin-specific MR
contrast agent has several potential advantages. Firstly, as the probe
does not bind to endogenous cross-linked elastin present in the normal
aortic wall, it allows for specific detection of areas of dysfunctional ma-
trix remodelling in active aortic vessel wall disease. Secondly, tropoelas-
tin MRI could allow for the direct localization and quantification of the
effect of treatments that aim at modulating tropoelastin turnover.
Thirdly, the use of T1 maps and imaging at a clinical field strength makes
our approach quantitative and clinically translatable. Finally, the versatility
of the probe to be chelated with radioisotopes makes it also suitable for
nuclear/hybrid imaging, further increasing its translational potential.
In conclusion, tropoelastin MRI identifies dysfunctional matrix remod-
elling that is specifically expressed in regions of aortic aneurysm or dis-
section and correlates with the development and rate of aortic
expansion. Thus, it may provide an additive imaging marker to the serial
assessment of luminal diameter for surveillance of patients at risk of or
with established aortopathy.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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Translational perspective
Abdominal aortic aneurysms and dissections are characterized by dysfunctional matrix remodelling, with accumulation of monomeric tropoelastin
rather than cross-linked elastin that may contribute to progressive dilation and rupture. Using a tropoelastin-specific magnetic resonance imaging
(MRI) contrast agent (Gd-TESMA), we demonstrate that aortic accumulation of tropoelastin is confined to regions of aortic dilation and that the pro-
portion of tropoelastin accumulation correlates with the rate of aortic expansion in a murine model of aortic dilation. As Gd-TESMA enhanced MRI
identified tropoelastin accumulation in human aneurysmal tissue, this approach may provide an imaging marker of disease activity and vessel wall in-
tegrity additional to serial measurement of aortic diameter.
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